<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

 

 

Ovarian Cancer PDX Models 
A Champions Model Cohort

A bank of meticulously curated ovarian  cancer PDX models directly derived from primary, metastatic, and pretreated patient tumors to support bladder cancer drug development research.

 

 

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

 

Ovarian Cancer PDX Model Cohort to Advance your Ovarian Cancer Therapies

Champions Oncology currently offers 60* clinically relevant Ovarian Cancer PDX models for oncology pharmacology studies and drug development, established from both primary and metastatic tumors, with many derived from patients previously treated with Standard of Care therapies. Of these, 52* models have been characterized using Next Generation Sequencing (WES and RNA-seq) and in vivo drug response testing, providing a diverse and robust dataset for evaluating biomarkers of response and non-response in ovarian cancer. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)

Champions' leading Ovarian Cancer PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Access to one of the largest  bank of ovarian cancer models with clinically relevant molecular
    and pathological characteristics on the market. 
  • Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
  • Includes models pretreated with advanced therapies like Liposomal doxorubicin, Topotecan, Docetaxel, Anastrozole and more.